search
Back to results

Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)

Primary Purpose

Type 1 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Psychoeducation to reduce diabetes distress and improve glycemic outcomes
Sponsored by
Joslin Diabetes Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes

Eligibility Criteria

14 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 14-25 years
  • Diagnosis of type 1 diabetes (according to ADA criteria)
  • Type 1 diabetes duration ≥12 months
  • A1c 7-13%
  • Smartphone or regular access to wifi via computer
  • Fluency in English at a 5th grade level or higher (based on investigator assessment of grade level in school or highest grade level achieved and presence in mainstream academic classes)

Exclusion Criteria:

  • Physical or mental health condition that in the determination of the investigators may limit the ability to fully participate in the study (e.g., autism)
  • Participation in another intervention study within the last 3 months
  • Currently pregnant or intending to become pregnant during the study (assessed by self-report)

Sites / Locations

  • Stanford UniversityRecruiting
  • Joslin Diabetes CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention Group

Control Group

Arm Description

The Intervention Group will receive the monthly intervention sessions during the first year of the study.

The Control Group will receive the monthly intervention sessions during the second year of the study (after assessment of primary outcomes at 1 year).

Outcomes

Primary Outcome Measures

Time in Range (TIR)
CGM data will be downloaded every 3 months to assess percent time in range (TIR) (70-180 mg/dL). The primary outcome will be change in TIR from 0 to 12 months for intervention group vs. control group.

Secondary Outcome Measures

A1c
A1c will be assessed every 6 months. Blood samples will be collected locally using uniform procedures and sent to the central laboratory at the University of Minnesota for analysis. Change in A1c from 0 to 12 months will be compared within and between the intervention group and control group.
Diabetes distress
Diabetes distress will be assessed every 6 months using the validated Problem Areas in Diabetes - Pediatric survey (PAID-Peds) and the Diabetes Distress Scale. Change in diabetes distress from 0 to 12 months will be compared within and between the intervention group and control group.
Attitudes toward diabetes device use
Attitudes toward diabetes device use will be assessed every 6 months using the validated Glucose Monitoring Satisfaction Survey and the Diabetes Technology Attitudes Scale. Change in attitudes toward device use from 0 to 12 months will be compared within and between the intervention group and control group.

Full Information

First Posted
June 7, 2022
Last Updated
June 15, 2023
Sponsor
Joslin Diabetes Center
Collaborators
Stanford University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT05413239
Brief Title
Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)
Official Title
Improving Glycemia & Reducing Diabetes Distress in Adolescents & Young Adults With T1D: Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 26, 2022 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Joslin Diabetes Center
Collaborators
Stanford University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In this 2-year randomized clinical trial, we will implement and assess the impact of a behavioral/psychoeducational intervention to reduce diabetes distress and improve glycemic outcomes in adolescents and young adults, aged 14-25 years, with T1D in order to optimize their short-term and long-term health.
Detailed Description
In this study, we will recruit 180 adolescents and young adults (ages 14-25) with type 1 diabetes for at least 1 year and suboptimal diabetes control (A1c 7-13%) to participate in a 2-year randomized clinical trial aimed at reducing diabetes distress and improving glycemic outcomes. Adolescents and young adults with type 1 diabetes represent a population that often has uncontrolled diabetes with elevated A1c levels and experiences diabetes distress, making such patients ideal for this study. Participants will be randomly assigned to one of two groups (control or intervention). The intervention group will participate in monthly intervention sessions with a research assistant during the first year of the study. Four sessions will focus on improving glycemic outcomes and 8 sessions will focus on reducing diabetes distress. The sessions will be conducted face-to-face or remotely. To ensure adequate recruitment and retention, the control group will participate in the intervention sessions during the second year of the study. Participants in both groups will use continuous glucose monitoring (CGM), with CGM data downloaded every 3 months. Participants in both groups will complete surveys and have A1c measured every 6 months. We will compare the two groups on percent time in target glucose range (70-180 mg/dL), A1c, and diabetes distress from baseline to 1 year. We hypothesize that the intervention group will have an improvement in percent time in range, A1c, and diabetes distress, compared with the control group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
The Intervention Group will receive the monthly intervention sessions during the first year of the study.
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
The Control Group will receive the monthly intervention sessions during the second year of the study (after assessment of primary outcomes at 1 year).
Intervention Type
Behavioral
Intervention Name(s)
Psychoeducation to reduce diabetes distress and improve glycemic outcomes
Intervention Description
The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting ~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
Primary Outcome Measure Information:
Title
Time in Range (TIR)
Description
CGM data will be downloaded every 3 months to assess percent time in range (TIR) (70-180 mg/dL). The primary outcome will be change in TIR from 0 to 12 months for intervention group vs. control group.
Time Frame
0, 3, 6, 9, 12, 15, 18, 21, and 24 months
Secondary Outcome Measure Information:
Title
A1c
Description
A1c will be assessed every 6 months. Blood samples will be collected locally using uniform procedures and sent to the central laboratory at the University of Minnesota for analysis. Change in A1c from 0 to 12 months will be compared within and between the intervention group and control group.
Time Frame
0, 6, 12, 18, and 24 months
Title
Diabetes distress
Description
Diabetes distress will be assessed every 6 months using the validated Problem Areas in Diabetes - Pediatric survey (PAID-Peds) and the Diabetes Distress Scale. Change in diabetes distress from 0 to 12 months will be compared within and between the intervention group and control group.
Time Frame
0, 6, 12, 18, and 24 months
Title
Attitudes toward diabetes device use
Description
Attitudes toward diabetes device use will be assessed every 6 months using the validated Glucose Monitoring Satisfaction Survey and the Diabetes Technology Attitudes Scale. Change in attitudes toward device use from 0 to 12 months will be compared within and between the intervention group and control group.
Time Frame
0, 6, 12, 18, and 24 months
Other Pre-specified Outcome Measures:
Title
Hypoglycemia experience
Description
Fear of hypoglycemia and confidence in hypoglycemia management will be assessed every 6 months with the Fear of Hypoglycemia Screener and the Hypoglycemia Confidence Scale. Change in hypoglycemia experience from 0 to 12 months will be compared within and between the intervention group and control group.
Time Frame
0, 6, 12, 18, and 24 months
Title
Health-related quality of life
Description
Health-related quality of life will be assessed every 6 months with the PROMIS Global Health Measure. Change in quality of life from 0 to 12 months will be compared within and between the intervention group and control group.
Time Frame
0, 6, 12, 18, and 24 months
Title
Diabetes incorporation/identity
Description
Diabetes incorporation/identity will be assessed every 6 months with the Accepting Diabetes And Personal Treatment (ADAPT) survey. Change in diabetes incorporation/identity from 0 to 12 months will be compared within and between the intervention group and control group.
Time Frame
0, 6, 12, 18, and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 14-25 years Diagnosis of type 1 diabetes (according to ADA criteria) Type 1 diabetes duration ≥12 months A1c 7-13% Smartphone or regular access to wifi via computer Fluency in English at a 5th grade level or higher (based on investigator assessment of grade level in school or highest grade level achieved and presence in mainstream academic classes) Exclusion Criteria: Physical or mental health condition that in the determination of the investigators may limit the ability to fully participate in the study (e.g., autism) Participation in another intervention study within the last 3 months Currently pregnant or intending to become pregnant during the study (assessed by self-report)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lori M Laffel, MD, MPH
Phone
617-732-2603
Email
lori.laffel@joslin.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lori M Laffel, MD, MPH
Organizational Affiliation
Joslin Diabetes Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Korey K Hood, PhD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Selma Alamarie
Email
salamari@stanford.edu
Facility Name
Joslin Diabetes Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brenden Morrissey
Email
brenden.morrissey@joslin.harvard.edu

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
If we are able to remove all HIPAA-defined identifiers from the final data set to eliminate the possibility of deductive disclosure of participants with unusual characteristics, the investigators will make the final data set available to interested researchers according to the NIH Data Sharing Policy and the criteria below.
IPD Sharing Time Frame
After all of the investigators' analyses, presentations, and publications of study findings are complete
IPD Sharing Access Criteria
If it is determined that data can be shared, data will be made available upon request to qualified persons only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are complete.

Learn more about this trial

Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)

We'll reach out to this number within 24 hrs